Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Boehringer Ingelheim
Harvard Business School
US Department of Justice
Covington
Johnson and Johnson

Generated: May 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,596,746

« Back to Dashboard

Which drugs does patent 6,596,746 protect, and when does it expire?

Patent 6,596,746 protects SPRYCEL and is included in one NDA.

Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-six patent family members in thirty-eight countries.

Summary for Patent: 6,596,746
Title: Cyclic protein tyrosine kinase inhibitors
Abstract:Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Inventor(s): Das; Jagabandhu (Mercerville, NJ), Padmanabha; Ramesh (Hamden, CT), Chen; Ping (Belle Mead, NJ), Norris; Derek J. (Trenton, NJ), Doweyko; Arthur M. P. (Long Valley, NJ), Barrish; Joel C. (Holland, PA), Wityak; John (Robbinsville, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/548,929
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,596,746
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,596,746
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,596,746

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKesson
Boehringer Ingelheim
Julphar
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.